Patents by Inventor Jeremy Richard Graff

Jeremy Richard Graff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of Prostate Cancer with eIF4E Antisense Compounds
    Publication number: 20140323543
    Abstract: The present invention provides methods of sensitizing cancer cells to docetaxel and inhibiting the growth of various tumors by employing a modified eIF-4E antisense oligonucleotide and docetaxel in combination.
    Type: Application
    Filed: April 25, 2013
    Publication date: October 30, 2014
    Inventor: Jeremy Richard Graff
  • Modulation of eIF4E expression
    Patent number: 8410074
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: April 2, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff
  • MODULATION OF EIF4E EXPRESSION
    Publication number: 20120283312
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Application
    Filed: July 13, 2012
    Publication date: November 8, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff
  • Combination therapy for the treatment of cancer
    Patent number: 8268797
    Abstract: The present invention provides methods of sensitizing lung cancer cells to cisplatin and inhibiting the growth of lung cancer tumors by employing a modified eIF-4E antisense oligonucleotide and cisplatin in combination.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: September 18, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Jeremy Richard Graff
  • COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20110301222
    Abstract: The present invention provides methods of sensitizing cancer cells to docetaxel and inhibiting the growth of various tumors by employing a modified eIF-4E antisense oligonucleotide and docetaxel in combination.
    Type: Application
    Filed: November 17, 2009
    Publication date: December 8, 2011
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Jeremy Richard Graff
  • COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20110280963
    Abstract: The present invention provides methods of sensitizing lung cancer cells to cisplatin and inhibiting the growth of lung cancer tumors by employing a modified eIF-4E antisense oligonucleotide and cisplatin in combination.
    Type: Application
    Filed: November 17, 2009
    Publication date: November 17, 2011
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Jeremy Richard Graff
  • MODULATION OF eIF4E EXPRESSION
    Publication number: 20100130589
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Application
    Filed: August 31, 2009
    Publication date: May 27, 2010
    Inventors: Susan M. Freier, Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff, Bruce William Konicek
  • Modulation of eIF4E expression
    Patent number: 7601700
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: October 13, 2009
    Assignees: Eli Lilly and Company, ISIS Pharmaceuticals, Inc.
    Inventors: Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff
  • MODULATION OF eIF4E EXPRESSION
    Publication number: 20090192106
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Application
    Filed: August 1, 2008
    Publication date: July 30, 2009
    Inventors: Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff
  • Modulation of eIF4E expression
    Patent number: 7425544
    Abstract: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: September 16, 2008
    Assignees: Eli Lilly and Company, ISIS Pharmaceuticals, Inc.
    Inventors: Kenneth Dobie, Eric G. Marcusson, Eric E. Swayze, Balkrishen Bhat, Jeremy Richard Graff